Literature DB >> 27322636

Intra-articular injections of mesenchymal stem cells (MSCs) as a treatment for hemophilic arthropathy.

E Carlos Rodriguez-Merchan1.   

Abstract

Intraarticular (IA) injections of mesenchymal stem cells (MSCs) in idiopathic osteoarthritis (OA) have shown encouraging results in the literature. Hemophilic arthropathy (HA) represents an enormous societal burden. The similarity between OA and HA is very limited. HA resembles much more to the rheumatoid arthritis because a presence of thick synovial membrane and large lymphocytes infiltration. However, in its final stages, HA resembles OA and that is when IA injections of MSCs are commonly used. In this article, we review the concept of IA injections of MSCs as a treatment for HA, using the literature on OA as an example. Regarding HA, only two experimental studies have been reported to date. Such studies stated that IA injections of MSCs appear to be efficacious for decreasing pain in patients with OA and HA. The use of IA injections of MSCs is thus a promising therapeutic modality for treating HA.

Entities:  

Keywords:  Hemophilia; MSCs; arthropathy; injections; intraarticular

Mesh:

Year:  2016        PMID: 27322636     DOI: 10.1080/17474086.2016.1203780

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  2 in total

1.  Diagnostic Values of Inflammatory and Angiogenic Factors for Acute Joint Bleeding in Patients With Severe Hemophilia A.

Authors:  Huijuan Xu; Ren Zhong; Kai Wang; Xuerong Li; Yanxia Zhao; Jian Jiang; Shaoyong Si; Lirong Sun
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 2.  Mesenchymal stromal cell and bone marrow concentrate therapies for musculoskeletal indications: a concise review of current literature.

Authors:  Christian Eder; Katharina Schmidt-Bleek; Sven Geissler; F Andrea Sass; Tazio Maleitzke; Matthias Pumberger; Carsten Perka; Georg N Duda; Tobias Winkler
Journal:  Mol Biol Rep       Date:  2020-05-25       Impact factor: 2.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.